Clinical Trial

Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase I, open-label, fixed-sequence, two-part drug-drug interaction study in healthy Chinese adults to evaluate the effect of multiple-dose rifampin (Part A) or itraconazole (Part B) on the single-dose pharmacokinetics of MDR-001, an oral GLP-1 receptor agonist.
Trial Details
NCT Number NCT07550621
Lead Sponsor MindRank AI Ltd
Conditions Healthy Volunteers (HV)
Enrollment 28 participants
Start Date 2026-05-06
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-06-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-24